Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study

BACKGROUND: To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate. METHODS: In this double-blind, placebo-controlled phase 3 trial, biologic-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaofeng, Liu, Ju, Liu, Xiumei, Wu, Lijun, Liu, Yi, Liao, Xiangping, Liu, Huaxiang, Hu, Jiankang, Lu, Xin, Chen, Linjie, Xu, Jian, Jiang, Zhenyu, Lu, Fu-ai, Wu, Huaxiang, Li, Ying, Wang, Qingyu, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185960/
https://www.ncbi.nlm.nih.gov/pubmed/35689239
http://dx.doi.org/10.1186/s13075-022-02821-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185960/
https://www.ncbi.nlm.nih.gov/pubmed/35689239
http://dx.doi.org/10.1186/s13075-022-02821-x

Ejemplares similares